Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Clinical trial NCT05724329 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05724329
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinomas

Start date: 2023-02-05
Primary completion: 2024-04-05
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.